Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging
Clicks: 12
ID: 301345
2014
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Star Article
3.3
/100
12 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
StarRanked #6 of 96 articles by views in European Heart Journal - Cardiovascular Imaging
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
administration.We recognize that in the setting of a variety of predisposing factors, varying cumulative dosages of recognized cardiotoxic agents, and use of other agents that are known to increase oxidative stress and compromise myocyte stability, the algorithm proposed in this document cannot be based on strong clinical data.Since the approval of trastuzumab, numerous agents have entered the therapeutic armamentarium, including the small-molecule tyrosine kinase inhibitors.It is difficult to make broad generalizations about these agents, because they often have different kinase targets.However, it appears that the most problematic are the agents that target vascular endothelial growth factor (VEGF) and VEGF receptors.These agents typically are associated with severe systemic arterial hypertension and ischaemic events.The development of CTRCD in these patients may be related to transient impairment of the contractile elements within the cell or to the increased afterload on a compromised ventricle.The most concerning of this group are the non-selective agents, including sunitinib and sorafenib, because these drugs can target up to 50 different kinases, in addition to the intended target. 12Because those "off-target" kinases play important roles in the heart and vasculature, the risk of toxicity is increased.As a result of the unspecific nature and predictability of myocardial damage, it is difficult to provide general recommendations regarding how to monitor patients receiving these agents.A number of attempts have been made to unify approaches to manage these patients, all stopping short of proposing guidelines; one attempt focused on arterial hypertension 13 and the other on CTRCD. 14Careful management of comorbidities was urged in these documents.Key points † Highly effective chemotherapeutic agents may cause CTRCD.† CTRCD has been classified as follows:(1) Type I CTRCD is characterized by anthracyclines.It is dosedependent, leads to cell apoptosis, and is therefore irreversible at the cell level.Early detection and prompt treatment may prevent LV remodelling and the progression to the HF syndrome.(2) Type II CTRCD is characterized by trastuzumab.It is not dose dependent, does not lead to apoptosis by itself, and is often reversible. II. Echocardiographical evaluation of cardiac structure and function in cancer patientsEchocardiography is the cornerstone in the cardiac imaging evaluation of patients in preparation for, during, and after cancer therapy, because of its wide availability, easy repeatability, versatility, lack of radiation exposure, and safety in patients with concomitant renal disease.In addition to the evaluation of LV and right ventricular (RV) dimensions, systolic and diastolic function at rest and during stress, echocardiography also allows a comprehensive evaluation of cardiac valves, the aorta, and the pericardium. 15Table 2 summarizes the recommended cardio-oncology-echocardiogram protocol.A. Left ventricular systolic function
| Reference Key |
openalex_W2068483637
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Juan Carlos Plana, Maurizio Galderisi, Ana Barac, Michael S. Ewer, Bonnie Ky, Marielle Scherrer‐Crosbie, Javier Gáname, Igal A. Sebag, Deborah A. Agler, Luigi P. Badano, José Banchs, Daniela Cardinale, Joseph R. Carver, M. Cerqueira, Jeanne M. DeCara, Thor Edvardsen, Scott D. Flamm, Thomas Force, Brian P. Griffin, Guy Jérusalem, J. E. Liu, Andreia Magalhães, Thomas H. Marwick, Liza Sanchez, Rosa Sicari, Hector R. Villarraga, Patrizio Lancellotti |
| Journal | European Heart Journal - Cardiovascular Imaging |
| Year | 2014 |
| DOI |
10.1093/ehjci/jeu192
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.